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Improved Survival Results from Early Detection
and Diagnosis of Testicular Cancer
by Douglas E. Johnson, M.D.
W. A. "Tex" and Deborah
Moncrief, Jr., Chair in Urology
Department of Urology
Testicular cancer is the most frequently occurring solid tumor in
men between the ages of 18 and 34
years and was, until recently, one of
y
the leading causes of death in this age
group. Fortunately, at a time when
the incidence appears to be rising,
Douglas E. Johnson
the mortality is showing a decline.
This decline in mortality can be directly attributed to two factors. First, the diagnosis is being made earlier as a result of the
efforts expended by a number of organizations, among them the
American Cancer Society and its local branches, co (I) educate
young men at risk for developing the disease as to its signs and
symptoms (see accompanying table) and (2) increase physicians'
index of suspicion, leading to earlier per formance of diagnostic
studies (such as scrotal ultrasonography and serum biologic
marker measurement). Second, this improvement in survival can
be attributed to the major advances made during the past decade
in developing and employing effective chemotherapy programs.
T h at a prompt diagnosis correlates with a lower stage of disease,
less morbidity, and more effective t herapy has been demonstrated.

Testicular Self#Examination
Since nine out of every 10 testicular rumors are discovered by
the patient himself, young men should learn to practice a two- co
three-minute "testicular self-examination" (see drawings) every
month and make self-examination a lifetime habit. Testicular
self-examination is best perfor med during or immediately after a
warm shower or bath, since heat causes the scrotum to relax,
allowing the testes co be in a more descended position. The man
takes one testis in his hand, fixes it in a comfortable position, and
slowly and gently rolls it between the thumb and index finger of
his other hand, checking for a lump, an area of increased firmness, or slight enlargement. He t hen repeats the examination on
the other testis. A man who makes monthly self-examination a
Lifetime habit can detect promptly any changes that occur in the
testes and can immediately seek medical consultat ion.

Types of Testicular Tumors
In addition co the findings on physical examination, the physician today has a num ber of noninvasive procedures that usually
allow him to establish the diagnosis of a testicular tumor before
recommending surgery. When a tumor is present, however, its
surgical removal is essential. not only to eliminate the local d isease but also to establish the type and extent of the rumor. This
information is prerequisite to det ermining the need for and rype
of any additional t herapy.
More than 95% of testicular rumors arise from the germ cells
and must be considered malignant. Although they have a wide
range of histologic appear ances, they can be conveniently
divided into two categor ies for treatment planning: seminoma
and nonseminoma. The remaining3% to 5% of testicular tumors
(nongerminal) arise from specialized elements (Leydig or Sertoli
cells) or from connective tissue and muscle and may be either
benign or malignant. Since these latter tumors are rarely encountered, we will not discuss them further here.

Seminoma
Seminomas account for 34% co 55% of germinal tumors. Their
biologic aggressiveness is relatively low grade, as evidenced by the
findings that mosc patients presenc wich early-stage disease and
metastatic progression that is usually systematic, extending flrst
to t he rerroperironeum and rhen ro rhe mediasrina/ and suprac/a-

vicular lymph nodes. E arly hematogenous spread is rare. Among
240 patients with seminomas seen at U T M. D . Anderson
Hospital over 25 years, only 3 (I%) had pulmonary disease at
diagnosis, and initial relapse occurred in the lungs in only 3 of
225 patients with scage 1or II disease. This predictable spread pattern together with an unusual radiosensitivicy results in a high
radiocurability of this disease.

SIGNS AND SYMPTOMS OF TESTICULAR CANCER
A lump on the testicle
Any enlargement of the testicle
Pain or discomfort in the testicle or scro tum
A change in the way the testis feels from mo nth co m onth
Enlargement o r tenderness of the breasts
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Testicular Cancer . ..
continued from page 1
Clinical assessment should include a carefully performed physical examination as well as a careful review of the results of a chest
roentgenogram, computed tomography (CT) scan of the retroperitoneum and pelvis, and blood chemistry studies including
liver function tests and serum titers for beta human chorionic
gonadotropin (B-HCG) and alpha-fetoprotein (AFP). In the past
we relied heavily o n pedal lymphangiograrns to identify small
metastatic deposits within the regional lymph nodes, but we
have eliminated this examination as a routine staging procedure.
We accept the fact that in a few patients the lymphangiogram
would have identified regional disease below the resolution
power of CT scans, thereby altering stage assignment. Recent
analysis of our data showed that neither treatment planning nor
prognosis is adversely affected by the absence of a lymphangiogram. Consequently, in attempting to contain medical costs
without sacrificing the quality of medical care, we chose to eliminate routine lymphangiography in evaluating patients with
seminoma. Furthermore, since CT scanning is performed with
contrast medium, which visualizes the kidneys, we were also able
to eliminate excretory urography as a separate procedure.
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Treatment recommendations are based on the extent of disease
detected by the above-mentioned studies. Patients whose disease
is limited to the testis or adnexa (stage I) receive elective regional
lymphatic irradiation. Treatment is given with a 6-MeV linear
accelerator delivering 25 Gy in 15 fractions over three weeks to
the periaortic nodes through parallel opposed rectangular portals and to the iliac and inguinal nodes through an anterior field.
A recent review of 263 patients with stage I seminorna of the testis treated by orchiectomy and adjuvant radiation at UTMDAH
indicated a total survival rate, corrected for deaths during that
period, of97% from 5 through 20 years. No recognizable longterm complications were noted in this group of natients.
Patients presenting with recroperitoneal tumor masses less
than 10 cm in diameter (stage IIA) receive a similar amount of
radiation with an additional 5-Gy boost to the involved area
thTough reduced fields. Whereas in the past we believed it necessary to treat prophylactically the next echelon of lymph nodes
(those in the mediascinal and supraclavicular regions) for possible
occult metastasis, reevaluation of the sites of relapse proved that
t his is not required. Consequently, we do not believe that
patients with seminoma need routine irradiation above the diaphragm. The five-year disease-free survival rate was 95% for 40
patients recently treated at UTMDAH who were in this category
and who received radiation therapy.
Patients presenting with advanced retropericoneal disease (a
mass larger than 10 cm}, with nodal disease above the diaphragm, or with extranodal disease such as pulmonary or bony
metastasis (stages Ila and ill) are treated primarily with systemic
chemotherapy. This represents a marked change in treatment
philosophy. Only a few years ago, patients with bulky retroperitoneal disease would have received total abdominal irradiation
followed by prophylactic irradiation to the mediastinum and the
supraclavicular regions, and patients with disease confined to the
lymph nodes above the diaphragm (supraclavicular and mediastinal regions} would also have received radiation as primary
treatment.
Today, for these patients, cisplatin-based chemotherapy has
replaced irradiation as primary therapy. Treatment consists of
intravenous cyclophosphamide, 1 gram per square meter of bod y
surface area, followed by sequential cisplatin at a dose of JOO milligrams per square meter of bod y surface area given on days 1, 7,
and 14.After4 to 6weeks' rest, a second course is given on days 1
and 7. If a complete response is obtained before the second course
of treatment, no additional therapy is delivered. If, however, a
complete response is not achieved until after t he second course of
treatment, a third course is administered in 4 to 6 weeks. A
review of 52 patients with advanced disease treated in chis manner has revealed a 92% long-term disease-free survival rate
(range: 44 to 188 weeks). Eighty-five percent of these patients
achieved a complete response with chemotherapy alone. However, when the retroperitoneal mass has been significantly
reduced but a residual three-dimensional mass remains, postchemotherapy irradiation is considered.
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Scrotum

Anatomy of th• mal• g•nho urlnsry systsm.

How to p erform testicular self-examination (TSE): Perform TSE during or after a warm sho.Ner or bath. (1)

Be aware that, in most men, the left half of the scrotum is lower than the right. (2) Holding the scrotum, take
one tes&cle and rd/ it gently between the thumb and fingers, checking for a lump, an area of new firmness or
softness, or a slight enlargement. (3) Check the epididymis, the comma-shaped organ extending from the top of
the testicle to behind it. Normally it is soft and slightly tender when pressed. (41Locate the spermatic cord that
comes up from the epididymis; normally, it feels like a firm, movable, smooth tube. Repeat the examination on
the other testicle.

As a result of the judicious use of our therapeutic options, the
five-year survival rate for all patients ·w ith testicular semi.noma
currently exceeds 95%.

Nonseminomatous Tumors
The management of nonseminomatous germ cell tumors of the
testis (NSGCTT) is in a state of flux as a result of the recent
development of chemotherapy regimens that effectively eradicate metast~ses. Consistently curative chemotherapy was first
introduced into the management of NSGCTT by Dr. Melvin
Samuels at UTMDAH during the early l 970s; he used a combination of vinblastine and bleomycin. Lacer, Einhorn at the University oflndiana demonstrated that a combination of cisplatin,
vinblastine, and bleomycin was likewise effective. Today, because
improved diagnostic studies (ultrasonography, · CT, and radioimmunoassays) detect metastatic foci earlier and a number of
combination chemotherapy programs are available to treat
metastatic disease, our attitudes about the roles of surgery and
radiotherapy are undergoing major changes.
Early in this century, when patients whose d isease appeared
confi ned to th e testis (stage I) were followed after orchiectomy by
observation alone, only 25% survived for sign ificant periods.
This unacceptable survival rate led to the routine use of retroperitoneal lymphadenectomy or radiotherapy, both of which
produced potentially devastating long-term complications.
Because today's sensitive diagnostic studies can determine so
much more reliably that disease is really stage I, we would like to
avoid this unnecessary morbid ity for patients with limited
NSGCIT. Accordingly, in October 1981 we began a pilot study
to evaluate the feasibility of a postorchiectomy surveillance program in a carefully controlled setting for patientS with NSGCIT.
Preliminary experience with surveillance alone after orchiectomy in patients with clinical stage l disease confirmed t hat a
"watch and wait" policy was safe and that those patients who
relapsed could be rendered free of disease with chemotherapy.
Eighty-two patients with NSGCTT whose evaluation at
UTMDAH following orchiectomy was negative for metastatic
disease (normal B-H CG and A FP serum levels, lymphangio-
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gram, CT scan, and chest x,ray) h ave been followed for at least
on.e year; 70% h ave been continuously free of disease. As
expected, 30 patients developed metastasis, but all but one were
rendered free of disease with chemotherapy and are alive, doing
well, today. In view of our experience, which has been confir med
by other investigators at a number of institutions worldwide, we
continue to recommend careful surveillance following orchieccorny for patients who have NSGCTT but no obvious regional
or visceral metastasis.
Current treatmenr options for patients present ing with
regional ret roperitoneal metastases whose disease is not
advanced ( s 10 cm mass; stage Il.J include (1) retroperitoneal
lymphade nectom y followed by adjuva n t chemotherapy for
patients at h igh risk for recurrence and (2) lymphadenectomy followed by expectant observation, addi ng chemotherapy only if
metastatic disease develops. Unfortunately, distant metastases
have occurred in 30% co 50% of the patients under expectant
observation. The recent demonstration of an 89% continuous
disease-free status for 100 patients with adva nced presentations
treated by Dr. Ch ristoper Logothetis in the Section of Genitouri nary Medical O ncology, alternating cisplati n, cyclophosph amide, and doxoru b icin with vinblastine and bleomycin
(cyclic ClSCAuNB1v), h as given us cause to adopt an individualized approach to patien ts with clinical stage IIAd isease. On one
hand, by introducing primary chemotherapy for patients with
highly metastatic pure embryonal carcinoma, we find we have
effectively eliminated the need for "double" therapy (retroperitoneal lymphadenectomy followed by chemotherapy) and have
maintained a 96% complete-response rate. On the ocher hand,
we have found that patients with teratomatous elements in the
primary tu mor benefit most from a p rimary ret roperitoneal
lymph node d issectio n, since they have a lower visceral metastatic potential and are most likely to have a persistent retroperiton eal mass requiring surgery after primary chemotherapy.
These patients, therefore , now undergo primary retroperitoneal
lymphadenectomy and are followed carefully, reserving chemo-

continued on page 8
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Gastrointestinal Radiotherapy Team Creates Atmosphere of Com
Radiotherapists ask all their patients not to lose weight.
In the rockbottom basement of
UT M. D. Anderson Hospital, the
Department of Clinical Radiotherapy promotes this theme by offering
patients eggnog instead of coffee,
even at 7 a.m. And because most
patients come at least once a day, five
days a week for five or six weeks,
\
patients and clin ic staff members
know each other, and the place has
Lester J. Peters
an aura of welcome, as if having
body parts x-rayed once or twice a day were the way the world
turns. Staff members rarely walk down a hall without greeting
everyone on all sides. Patients share information about their illness and treatment, and often the conversation turns to where
they come from and how they need to get back there, to the job
or the children or the home in Odessa, Texas.
For patients from out of town who will go home for the weekend, the radiotherapy staff's custom is to make their appointments early on Fridays and late on Mondays. For Houston people
who work while they are being treated- and there are many who
manage to do this- the custom is to make the appointments convenient and to keep people waiting as Ii ttle as possible. That, anyway, is the intent.

Outer and Inner Changes
"One of our major goals in recent times," said lester J. Peters,

M.D., head of the Division of Radiotherapy and chairman of the
Department of Clinical Radiotherapy, "has been to deinstitu-

Small bowel af'lift with
patient in prone posilion

Vav of the open-tabletop device, the "bellyboard," arrJ d the small
bowel shift it produces in patients undergoing radiotherapy fa- gastroin
testinal cancer.
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tionalize the place. We've tried to do everything we can to make
the atmosphere friendly and receptive, and we've nowhere near
competed that task."
Peters described redecoration of patient areas and installation
of more comfortable furniture and signs and directions that are
easier to follow, and the creation of a clubroom for the many
patients who come for treatment twice a day. "But none cJ. that
means anything unless we deliver the best possible treatment,"
he said. "We try to bring particular skills to bear by having all of
our faculty members subspecialize so that we become experts in
one or two areas of cancer radiotherapy.
"This concentration," Peters said, "makes it easier for our physicians to interact with the surgeons who specialize in treating
specific types of cancer and with the medical oncologists, so that
we form more cohesive interdisciplinary groups than would be
possible if every one of the radiotherapists were treating many
types of patients."
Anderson HospitaEis also fortunate, Peters said, in having a
great deal of technical capability. "Although that's important,
it's less important than the first requirement, which is medical
skill arntjodgmem::-You can· hav~ fancy-equipment and still not
do good radiotherapy. On the other hand, if you're a very good
radiotherapist, you can get by with less fancy equipment. Of
course, if you've got both, you're in great shape, and that's what
we aim to achieve."
"This is not a static specialty," he said. "A lot of people think
that radiotherapy has been around for 80 years and is in a rut.
Nothing could be further from the truth. The practice of radiotherapy is changing and evolving, and we are constantly adapting treatment to take advantage of new discoveries- to provide
better control of the cancer and to reduce the side effects of
treatment."
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fort and Confidence for Patients

makes sure that all details of patients' tests and quality controls
are done correctly."
On his clinic days, Monday, Wednesday, and Friday afternoons, Rich and his resident physician- earlier this year, this
was Lori Hughes, M.D.- see each patient at least once a week to
discuss treatment, change it if necessary, answer questions, check
on tests. Rich's team members put a great deal of effort into communicating with patients and with each other. They stay in
touch with referring physicians, particularly the doctors patients
will return to after they have completed their treatments at
Anderson.

Constantly Working on Treatment Flow

Flora Johnson, a technician, at the treatment control console while chief
technologist Velda Croy and Tyvin A. Rich look over the patient's

record.

T he Gastrointestinal Cancer Treatment Team
T yvin A Rich, M.D., an associate professor of radiotherapy,
specializes in treating patients for gastrointestinal (GI) cancer.
Among the leading staff members on his team are ·head nurse
Linda McCallister, who is also the radium curator, clinic nurse
Ellen Sitton, and chief technologist Velda Croy. The GI cancer
team treats about 25 patients a day. Most are ambulatory, but a
third are very ill patients brought from the inpatient unit, usually for palliative treatment.
Rich developed the "bellyboard," an open-tabletop device
with a large hole by which a patient's smal I bowel is shifted out of
the radiation beam's way (see drawing). He and his staff know
and often hear from their patients that it's not a great pleasure to
lie on this board for up to an hour, immobile, while being marked
and measured for radiotherapy during the simulation session.
Evidently, the bellyboard's safety advantages rate higher than
the discomfort.
Rich described a patient's odyssey in his service, from evaluation to treatment simulation to daily treatment. "The simulation," Rich said, "sets up the geometry of treatment. We cake
radiographs of the area to be irradiated and obtain a computer
contour, a process that involves the technical and dosimetry
staff. After that, the actual treatment should flow smoothly,
because we know exactly what we want to do. We typically treat
patients over a period of four to seven weeks. During that time
our technical staff delivers the treatment and our nursing staff
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As to inrernal communication, Rich stressed the technical
staff's need to know the patient's whole treatment, not only the
daily requirements. "We are continually trying to refine that
process of communicating among ourselves and our patients," he
said. "When the patient comes in for the first treatment and the
tech nician walks out to the waiting room and says, 'Come in,
Mr. Robinson, we're ready for you,' that's the culmination of
everything that's been done so far. We want to make sure that
there is no problem and that the patient feels absolutely comfortable and confident. We have to improve this constantly. And if
someth ing doesn't work at the physician's level, yes, we will
change it. That is why the treatment team works so closely with
me to develop the flow of treatment, not only from a technical
but also a nursing standpoint."
Sitton, a nurse in the radiotherapy clinic for 11 years, talked
about the inevitable side effects, which may vary from mild to
severe forms of fatigue, diarrhea, and loss of appetite. That is why
patients are asked to try to maintain their weight, often with a
dietician's advice.
Early in treatment, she said, patients usually don't experience
adverse effects. "But as we get into the treatment, we expect to
see some evidence ofside effects. And the earlier we catch these,
the more comfortable a patient will be throughout the trearment.
Because the only way to stop side effects is co stop treatment, and
that, of course, is nm what we wane to do."
"I don't think radiotherapy will ever be cocally rid of all side
effects," Rich said. "Bue we've learned from technology and biology and from understanding each anatomic site how to maximize the effect of radiotherapy on the tumor and minimize the
effect on the patient. T hat's the name of the game."

Progress in Techniques
But do the staff members get tired and burned out?
"Once in a while," Sitton said. "It's a temporary thing, and
that's why we need co take vacations. But I always come back. It's
the area I care about and am interested in, and I enjoy working
with those patients."

continued on page 8

5

OntoLog,____ _ _ _ __
Current Laboratory Research Modernizes
Traditional Chinese Herbal Medicine
For more than two thousand years,
Chinese physicians have used traditional herbal medicines to build up a
patient's natural defenses against
cancer and other diseases. During
the pasr several years in the Department of Clinical Immunology and
Biological Therapy ar UT M . D.
Anderson Hospital, Giora Mavligir,
M.D., and two visiting Chinese scientists have been studying two of
those herbs, attempting to isolate Giora M. Mav/igit
and characterize components that
may restore immune function.
"I've always been impressed with
traditional medicine, because if it
were not good, it wouldn't have
lasted for so long. It's human nature
to seek the best and filter out what
doesn't work," said Mavligit. Yen
Sun, M .D., a visiting scientist from
the People's Republic of China, was
the first to suggest to Mavligit chat
they use modern research tools to
investigate these traditional herbs in Da-Tong Chu
the laboratory. The physicians' tests
of simple water extracts of two herbs, Ligustrnm and Astragalus,
indicated the presence of significant immune-restorative agents.
For in vitro testing, the researchers used an immunobioassaylocal xenogeneic graft-versus-host reaction-in laboratory rats, a
test they have used since the late 1970s to evaluate T-cell function. "This bioassay sets up a competition between the cells chat
we inject-the graft-and the animal chat's supposed to reject
that graft. If che animal is immunologically competent, it will
reject the graft. If we partially suppress the animal's immune system (for example, with cydophosphamide, a widely used anticancer drug) but give it a cell graft from a patient with advanced
disease, the animal that is only partially immune-suppressed can
still reject the graft because its immunity is stronger than chat of
the patient," said M avligit. "What we have is a very delicate balance of two systems, one of which is artificially suppressed and
the other suppressed by the growing cancer,'' he said.

Complete Immune Restoration
The results showed that cells (from cancer patients) incubated
in vitro with the herbs had their immunity restored completely so
that they were as immune competent as cells from normal
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donors. Other immune-restorative agents the researchers rested,
such as cimetidine, indomethacin, and isoprinosine, restored
immunity only partially.
When Da-Tong Chu, M.D., followed Sun in the exchange program, Chu and Mavligit decided to determine the nature of the
active component in the crude extract of Ascragalus membranaceus. With the help of Newporr Pharmaceuticals, they obtained
eight fractions from a column-fracrionared extract of the herb.
They rested all eight and determined chat fraction J, with a
molecular weight of 20,000-25,000, was the most potent. In testing fraction 3 in vitro, they repeated the studies of xenogeneic
graft-versus-host reaction. In vivo tests were done by giving the
rats fraction 3 and cyclophosphamide injections. As expected,
cyclophosphamide suppressed the animals' immune system, but
fraction 3 restored it to the extent that the animals rejected normal donor grafcs completely.
The researchers' third step was to add fraction 3 to experimental interleukin-2 (IL-2) treatments. The development of IL-2 has
generated much interest in cancer resea rch, but its antitumor
effect is mitigated by its often extreme toxicity at the high doses
needed. Blood cells contain precursors for lymphokine-activated
killer cells, called LAK cells, that are generated when the blood is
incubated with IL-2. When the LAK cells are applied to tumor
cells in vitro, the LAK cells destroy the tumor cells. The higher
the dose of IG2, the greater the activity of the killer cells; but in
a clinical setting, the higher the dose, the greater the toxicity
as well.
Mavligit and Chu wanted to see if using fraction 3 in concert
with lower doses of IL-2 would achieve the same level of LAKcell activity as higher doses of IL-2 given alone. They found that
adding fraction 3 of Astragalus potentiated IL-2 so that only
one-tenth of the dose was needed to achieve the same LAKcell activity in vitro. They also found that they were able co
reduce the ratio ofLAK cells to tumor cells needed co achieve the
same result.
"We still don't know if fraction 3 also potentiates the toxicity of
IL-2," said Mavligit. "We know that we can potemiate the biologic activity oflL-2 with fraction 3, but the Chinese herbs are far
from being an FDA-approved drug. So now we are looking for
another biological response modifier that is already available for
clinical studies to do the same thing," he said.
0

Physicians who desire additional information may write Giora
Mavligit, MD. , Department of Clinical Immunology and Biological
Therapy, Box 41, The University of1exas M. D. Anderson Hospital
and Tumor Institute at Houston, 1515 Holcombe Boulevard, Houston,
'Texas 77030.
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T HE FIVE PRINCIPLES OF CANCER TREATMENT

The Chinese experience in the treatment of cancers
dates back more than two thousand years and has
evolved into the five principles of herbal medication
related to cancer treatment today. (There is no direct
correlation between the principles of traditional Chinese medicine and Western medicine; therefore, it is
impossible to translate the Chinese concepts completely
into English.) These drugs are given by prescription,
under medical supervision. The physician selects the
types and quantities of herbs needed by each patient.

1987 Fall Conferences
Sponsored by The University of Texas M. D. Anderson Hospital
and Tumor Institute at Houston:

September 29-0ctober 2
O ncology N ursing Conference Ill
"Oncology Nursing on a Continuum."
Westin Galleria Hotel, Housten

Ocwbe-r II -I 4

Fu Zheng Qu Xie-Literally means promoting or
enhancing the natural host defense mechanism to eliminate the external or internal pathogenic factors and
products.

Ninth Annual Pharmacy Symposium on Cancer
Chemotherapy
Westin Galleria Hotel, Houston

October 29-30
Fourth Annual Administrative Conference

Qu Yu H uo Xue-Literally means eliminating the
stasis and activating the blood. Chinese medicine uses
blood-activating and sludge-eliminating drugs to dissolve stagnant blood and maintain the circulation.

"Management of Hazardous Materials: Practical Approaches for
the Healthcare Industry."
Marriott Hotel -Asrrodome, Houston

November 8-11
Fortieth Annual Symposium on Fundamental Cancer Research

Qing Re Jie D u-Literally means dissipating heat
and detoxifying. This is the therapeutic method of
treating various carbuncles, cellulicis, sores, feruncles,
and nameless swellings and toxins (including cancer)
with heat-clearing and texin-eliminating drugs.

Ruan Jian San Jie- Licerally means softening and
dissolution of hard masses. This includes phlegmeliminating, sludge-dissolving, hardness-softening, and
mass-dispersing drugs, and it is used to treat swelling
and masses formed by accumulations of fluids, as in
lymphadenopathy, goiter, abdominal masses, and so
forth. The principle sounds strange from the viewpoint
of Western medicine, but it benefits some patients,
including patients with cancer.

Yi Du Gon g Du-Literally is the use of poisons as
antidotes to treat diseases such as leprosy, pyogenic
infection, and tumor.

Vol. 32, No. 3

"Genetic Mechanisms and Cancer."
Westin Galleria Hotel, Houston

November I 1-14

Thirty-first Clinical Conference
"Recent Advances in the Systemic Therapy of Genitourinary
Malignancies."
Westin Galleria Hotel, Housron

For more information, write Office of Conference Services, HMB Box
131, The University of Texas M. D. Anderson Hospital and Tumor
Institute at Houston, 1515 Holcombe Boulevard, Houston, Texas
77030. Ph.one (713) 792-2222.

READER SURVEY RESPONSES
Last issue, we included a reader survey. At this time, more
than 450readers have responded. We will include a detailed
analysis of the survey results in the October-December
issue. Meanwhile, our thanks to all for their responses,
encouragement, and constructive criticism.
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Testicular Cancer ...

Gastrointestinal Radiotherapy . ..

omtinued from page 3

continued from page 5

therapy only for the ones who later show evidence of visceral
metastasis.
Patients presenting with advanced regional metastasis ( > 10
cm retroperitoneal mass; stage II8) or visceral metastasis (stage III)
are treated initially with systemic chemotherapy. As stated previously, we have achieved an 89% continuous disease-free survival
rate using cyclic CISCA11 /YB1v chemotherapy. Although the
acute toxicity of this therapy is formidable, only one patient died
as a result of chemotherapy, and the long-term toxicity appears
less than that of other currently used regimens.

"Yes, you can get burnout," said Croy. "But I see a lot of progress. I've been in oncology since 1973 and I've seen progress in
techniques. This has reduced the side effects of treatment and in
certain circumstances led to better cure rates. One problem I see
is that the technical staff members, who focus on the actual
button-pushing and setting the patient up, don't have the immediate rewards of seeing the people come back for follow-up visits
-unless the patients go down to the unit to say hello, which they
often do."

Conclusion
Therapy for patients with germ cell tumors of the testis is
undergoing major changes, brought about by the availability of
an ever-increasing number of curative chemotherapy programs.
The goal is no longer merely cure, but rather maintaining the
high cure rates now obtainable while at the same time limiting
therapy and reducing both acute and long-term sequelae. Oncologists can be applauded for many of the recent gains made
against testicular cancers. However, we need more awareness
among young men and their physicians of the signs and symptoms of disease, and we need to encourage greater practice of testicular self-examination, especially by those who are between 18
and 34 years old-those who are at the greatest risk for developing testicular cancer. In this way, the disease can be detected at
an earlier stage, requiring less extensive therapy.

Physicians who desire additional information may write Douglas E.
Johnson, MD., Department of Urology, Box 110, The University of
Texas M. D. Anderson Hospital and Tumor Institute ac Houston,
1515 Holcombe Boulevard, Houscon, Texas 77030.
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Next Step
To improve the cure rate dramatically in GI cancer, Rich said,
the next focus has to be on disseminated disease. "But we should
not lose sight of the fact that, as more advances are made in treating and curing patients with disseminated d isease, the more
important is it to provide a high quality of care in treating the
patient's local disease."
A strong message in radiotherapy in the last decade, he said,
has been to use conservative surgical and radiorherapeutic techniques so that patients can maintain a normal lifescyle. As has
been done in conservative breast cancer treatment, the GI
oncologists are developing new techniques of conservative rectal
cancer treatment to save patients from having permanent
colostomies.
"This will be an advance for GI radiotherapy," Rich said. "I
believe chose things are ignored when one looks at survival
curves. Our goal is not only to improve survival but to provide
better and more acceptable local therapy. This we are learning
codo."

Physicians who desire cuulitional information may write T yvin A.
Rich, M.D., Department of Clinical Raaiotherapy, Box 97, The
University of Texas M. D. Anderson Hospical and Tumor lnsticute
at Houscon, 1515 Holcombe Boulevard, Houston, Texas 77030.
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